TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33270026

Group type: EXPERIMENTAL
Intervention: WeChat intervention providing breastfeeding knowledge and promotion information weekly from third month of pregnancy to 6 months postpartum
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: WeChat intervention
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (no WeChat intervention)
Number of subjects: 344
Study: 34543474

Group type: EXPERIMENTAL
Intervention: Proactive management with Cal/BD foam (twice weekly)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Reactive management with vehicle foam (twice weekly)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Cal/BD foam (once daily) during initial 4-week phase
Number of subjects: 521
Study: 34023810

Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated to maximum 26 mg/day)
Number of subjects: 58
Study: 32345650

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BRAVO risk engine predictions
Number of subjects: 0
Study: 32216143

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 20
Study: 35590054

Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 ml
Number of subjects: 17
Study: 34021976

Group type: EXPERIMENTAL
Intervention: AI system for automatic recognition of cephalometric landmarks
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Cleft lip and/or palate
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Dental age, orthodontic appliances, and overjet
Number of subjects: 1785
Study: 36004368

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (YBLI) for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (SC) for 12 weeks
Number of subjects: 72
Study: 35075109

Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone (ixa-dex)
Number of subjects: 122

Group type: COMPARATOR
Intervention: pomalidomide-dexamethasone (pom-dex)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ixa-dex
Number of subjects: 122

Group type: COMPARATOR
Intervention: pom-dex
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ixa-dex vs pom-dex
Number of subjects: 122
Study: 33449919

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exendin(9-39)NH2 infusion during acarbose treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Exendin(9-39)NH2 infusion during placebo treatment
Number of subjects: 15
Study: 32320843

Group type: EXPERIMENTAL
Intervention: Brief advice combined with 1-week sample of nicotine replacement therapy (NRT) and active referral to smoking cessation services
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Brief advice only (usual care)
Number of subjects: 1148
Study: 35894681

Group type: EXPERIMENTAL
Intervention: Moderate-intensity blood flow restricted walking (BFR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Jogging
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity BFR-walking
Number of subjects: 16
Study: 33874750

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401

Group type: EXPERIMENTAL
Intervention: SGLT2i (pooled from 4 CVOTs)
Number of subjects: 4401

Group type: EXPERIMENTAL
Intervention: SGLT2i (pooled from 4 CVOTs, lowest eGFR subgroup)
Number of subjects: 4401
Study: 35805342

Group type: EXPERIMENTAL
Intervention: Stand-biased desk
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional desk
Number of subjects: 99
Study: 32281219

Group type: EXPERIMENTAL
Intervention: Ultrasound screening for vasa previa in perinatal centers
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Ultrasound screening for vasa previa in primary facilities
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Incidence of vasa previa in perinatal centers
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Incidence of vasa previa in primary facilities
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Referral to tertiary hospital for VP diagnosis in primary facilities
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Routine hospitalization in perinatal centers
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Steroid administration in perinatal centers
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Median gestational age at planned cesarean section in perinatal centers
Number of subjects: 377

Group type: COMPARATOR
Intervention: Median gestational age at planned cesarean section in primary facilities
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Survival outcomes of reported cases of vasa previa
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Emergency cesarean section outcome
Number of subjects: 377
Study: 35329011

Group type: EXPERIMENTAL
Intervention: Group-based core stability exercises
Number of subjects: 46

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 46
Study: 34819017

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (225 mg)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 32249589

Group type: EXPERIMENTAL
Intervention: Genetic liability to migraine
Number of subjects: 59674
Study: 35856361

Group type: EXPERIMENTAL
Intervention: L-carnitine (15 g/bag, orally, twice a day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: CoQ10 (10 mg tablet orally, thrice daily) with Vitamin E (100 mg tablet orally, thrice daily)
Number of subjects: 143
Study: 33398905

Group type: EXPERIMENTAL
Intervention: Virtual reality headset (videos)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 36173970

Group type: EXPERIMENTAL
Intervention: Triage by a rheumatologist in primary care
Number of subjects: 544

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 544
Study: 34275745

Group type: EXPERIMENTAL
Intervention: Educational intervention program (2 face-to-face individual instructional sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 33012200

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33930024

Group type: EXPERIMENTAL
Intervention: Recent deworming
Number of subjects: 6089

Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status
Number of subjects: 6089

Group type: EXPERIMENTAL
Intervention: Higher education level of household head
Number of subjects: 6089

Group type: EXPERIMENTAL
Intervention: Use of improved sanitation facilities
Number of subjects: 6089
Study: 33032778

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Action-planning leaflet
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo for atorvastatin
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo for omega-3
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 800
Study: 35018413

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 134
Study: 32961034

Group type: EXPERIMENTAL
Intervention: Macimorelin 2.0 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32358608

Group type: EXPERIMENTAL
Intervention: Online Acceptance and Commitment Therapy
Number of subjects: 30
Study: 36216414

Group type: EXPERIMENTAL
Intervention: Dual HIV/syphilis self-testing arm
Number of subjects: 330

Group type: COMPARATOR
Intervention: Single HIVST arm
Number of subjects: 330

Group type: COMPARATOR
Intervention: Site-based testing arm
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 330
Study: 32981856

Group type: EXPERIMENTAL
Intervention: Transradial angiography (TRA)
Number of subjects: 12118

Group type: COMPARATOR
Intervention: Transfemoral angiography (TFA)
Number of subjects: 12118
Study: 34359042

Group type: EXPERIMENTAL
Intervention: Early administration of 1.0 g/kg of 20% mannitol (immediately after anesthesia induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine administration of 1.0 g/kg of 20% mannitol (at the time of skin incision)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early administration of 1.0 g/kg of 20% mannitol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine administration of 1.0 g/kg of 20% mannitol
Number of subjects: 100
Study: 34548383

Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks for 24 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks until week 96
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 35295200

Group type: EXPERIMENTAL
Intervention: Preoperative Cryopreservation (CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Treated (NT)
Number of subjects: 0
Study: 34298559

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255
Study: 32622071

Group type: EXPERIMENTAL
Intervention: 600 IU daily cholecalciferol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3750 IU daily cholecalciferol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 35137728

Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33647273

Group type: EXPERIMENTAL
Intervention: Daily acute intermittent hypoxia combined with walking practice (AIH + WALK)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SHAM combined with walking practice (SHAM + WALK)
Number of subjects: 11
Study: 36201607

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine oral rinse
Number of subjects: 103

Group type: COMPARATOR
Intervention: Listerine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Saline oral rinse
Number of subjects: 103
Study: 32330117

Group type: EXPERIMENTAL
Intervention: Focused compression (VasoStat; Forge Medical)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Balloon compression device (TR Band; Terumo Medical)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 52
Study: 33999544

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (tailored, progressive rehabilitation including strength, balance, mobility, and endurance), initiated during or early after hospitalization and continued for 36 outpatient sessions.
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (tailored, progressive rehabilitation)
Number of subjects: 349
Study: 32597700

Group type: EXPERIMENTAL
Intervention: Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD)
Number of subjects: 25
Study: 34772324

Group type: EXPERIMENTAL
Intervention: Sugar (glucose) solution
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-nutritive sweetener (aspartame) solution
Number of subjects: 61
Study: 33704185

Group type: EXPERIMENTAL
Intervention: Alloderm-RTU
Number of subjects: 62

Group type: COMPARATOR
Intervention: DermACELL
Number of subjects: 62
Study: 34029328

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy, provided within 72 hours after a traumatic event, consisting of three sessions.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-directive support (control group).
Number of subjects: 32
Study: 34543068

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training for 1 year (n=30)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Attention control for 1 year (n=16)
Number of subjects: 46
Study: 35177254

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 190

Group type: COMPARATOR
Intervention: Microscopic technique
Number of subjects: 190
Study: 33852723

Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating IGF-1
Number of subjects: 2069

Group type: COMPARATOR
Intervention: High GRS of IGF-1
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating IGFBP-3
Number of subjects: 2069
Study: 33150410

Group type: COMPARATOR
Intervention: Previous recreational PA of 0 MET-hours/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Previous recreational PA of 0.1-9.9 MET-hours/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Previous recreational PA of 20-29.9 MET-hours/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Previous recreational PA of 30-39.9 MET-hours/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Previous recreational PA of ≥40 MET-hours/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Mentally active SB of 7-14.9 h/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Mentally active SB of 15-20.9 h/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Mentally active SB of ≥21 h/week
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Passive SB of 3-3.9 h/day
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Passive SB of 4-4.9 h/day
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Passive SB of ≥5 h/day
Number of subjects: 3228
Study: 33402037

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anticoagulation (usually apixaban)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Any antithrombotic therapy
Number of subjects: 75
Study: 35475921

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) treatment (110 mmHg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static compression (SC) garment (20-30 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment control (CTL)
Number of subjects: 30
Study: 33246873

Group type: EXPERIMENTAL
Intervention: Individualized self‐management combined with physical therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physical therapy intervention
Number of subjects: 53
Study: 35133617

Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 707

Group type: COMPARATOR
Intervention: trastuzumab-EU
Number of subjects: 707
Study: 32891506

Group type: COMPARATOR
Intervention: Single preoperative intra-vesical instillation of mitomycin C (pre-TURB instillation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Single immediate postoperative intra-vesical instillation of mitomycin C (post-TURB instillation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (pre-TURB and post-TURB instillation)
Number of subjects: 35
Study: 36361203

Group type: EXPERIMENTAL
Intervention: Family-based multifaceted economic empowerment (EE) intervention
Number of subjects: 702

Group type: COMPARATOR
Intervention: Control arm (not receiving EE)
Number of subjects: 702
Study: 33546622

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 261

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 261
Study: 33424006

Group type: EXPERIMENTAL
Intervention: E-learning program (5 training sessions)
Number of subjects: 221
Study: 35109492

Group type: EXPERIMENTAL
Intervention: DECENT programme
Number of subjects: 217

Group type: COMPARATOR
Intervention: Printed educational materials (control)
Number of subjects: 217
Study: 33248391

Group type: EXPERIMENTAL
Intervention: Active intervention (Wave 1) starting in Year 1
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control (Wave 2) starting in Year 3
Number of subjects: 67
Study: 36170789

Group type: EXPERIMENTAL
Intervention: Health information
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Health information plus hypocrisy inducement
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study: 33769679

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study: 34543741

Group type: EXPERIMENTAL
Intervention: ICG group (fluorescence imaging-guided lymphadenectomy)
Number of subjects: 514

Group type: COMPARATOR
Intervention: non-ICG group (conventional lymphadenectomy)
Number of subjects: 514
Study: 35495879

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation training based on routine nursing (experimental group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Image enhancement algorithm processing
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation training (both groups)
Number of subjects: 70
Study: 32046753

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) applied once within 48 hours of menstruation at six abdominal myofascial trigger points.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham rESWT (placebo control) applied on the same sites but without energy input.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups will be assessed for changes using the Zung Self-rating Anxiety Scale and Self-rating Depression Scale.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) changes in brain regions will be assessed.
Number of subjects: 36
Study: 34348351

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IVAI) treat-and-extend (T&E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IVAI) T&E plus sham photodynamic therapy (PDT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IVAI) T&E plus standard fluence PDT with verteporfin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IVAI) T&E
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IVAI) T&E plus sham PDT
Number of subjects: 50
Study: 33633278

Group type: EXPERIMENTAL
Intervention: Caffeine (3 × 150 mg caffeine daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Withdrawal (3 × 150 mg caffeine for 8 days, then switch to placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (3 × placebo daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine and Withdrawal conditions
Number of subjects: 20
Study: 35499655

Group type: EXPERIMENTAL
Intervention: Helioseal F Plus
Number of subjects: 92

Group type: COMPARATOR
Intervention: Helioseal F
Number of subjects: 92
Study: 33907800

Group type: EXPERIMENTAL
Intervention: Parietex ProGrip™ mesh-supported closure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Primary closure (control group)
Number of subjects: 200
Study: 33201503

Group type: EXPERIMENTAL
Intervention: 75 μM Cd
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 μM Cd
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cd stress
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 M NaCl extraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cd concentrations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uronic acid, total sugar contents, PME activity
Number of subjects: 20
Study: 32568470

Group type: EXPERIMENTAL
Intervention: Cavit G
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 54
Study: 34171493

Group type: EXPERIMENTAL
Intervention: Parent training intervention (12 therapy sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 33354964

Group type: EXPERIMENTAL
Intervention: Cereal grains and cereal products
Number of subjects: 56
Study: 35590395

Group type: EXPERIMENTAL
Intervention: Regular symptom monitoring with feedback using the Integrated Palliative Outcome Scale‐Renal (IPOS‐Renal) survey
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Regular symptom monitoring with feedback
Number of subjects: 2400
Study: 33624806

Group type: EXPERIMENTAL
Intervention: Elinzanetant 120 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32455565

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI) with a customized low glycemic index diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (SC) involving generic counseling about healthy diet and physical activity
Number of subjects: 0
Study: 35014030

Group type: EXPERIMENTAL
Intervention: TRUE Dads program participants
Number of subjects: 1042
Study: 33742316

Group type: EXPERIMENTAL
Intervention: Single intravesical trigonal-only injection of OnabotulinumtoxinA
Number of subjects: 45

Group type: COMPARATOR
Intervention: 20 trigone-sparing injections of OnabotulinumtoxinA
Number of subjects: 45
Study: 35822358

Group type: EXPERIMENTAL
Intervention: Rapid Axial Roll Test (RART)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional Roll Test (SRT)
Number of subjects: 400
Study: 33710268

Group type: EXPERIMENTAL
Intervention: Real-world evidence studies on diabetes treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: New-user active comparator cohort design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propensity score analyses
Number of subjects: 0
Study: 32897130

Group type: EXPERIMENTAL
Intervention: Passport to Wellness (PtW) intervention with peer support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison group lacking peer support
Number of subjects: 80
Study: 33653674

Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction (PRR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control arm (no PRR)
Number of subjects: 153
Study: 33574323

Group type: EXPERIMENTAL
Intervention: Awareness of COPD among residents who had heard of it (n = 49)
Number of subjects: 5420

Group type: EXPERIMENTAL
Intervention: Responses from residents who had never heard of COPD (n = 5371)
Number of subjects: 5420
Study: 36122605

Group type: COMPARATOR
Intervention: Nystatin oral suspension (Control‐100,000IU/mL; 4 × /day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trusoft relined without nystatin (Tru)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trusoft relined with nystatin (Ny)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trusoft relined with chlorhexidine diacetate (Chx)
Number of subjects: 40
Study: 33398922

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural social skills training (CBSST)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 203